HHS collaborated with Amazon to produce a safety authorization that any agency can reuse to cut procurement expenses.

Competition planned for massive cloud storage contract.

The tipping point at which tablets become the planet’s dominant personal computing device is nigh.

The administration's top tech executive will retain his duties as federal CIO.

Augmenting psychiatric diagnosis with data

DHS lets the companies sell government-furnished protections against malware spotted by intelligence officials.

Hagel promised a plan within 30 days. That was more than 30 days ago.

Security and budgets remain concerns.

Service wants to make the bidding process more accessible to start-ups.

Pentagon disclosed security approvals for Apple iOS and BlackBerry 10 mobile devices.

A White House executive order could conflict with pending federal acquisition rules.

A far-flung team is trying to build the first digital lifeform to work out the basic principles of the brain.

Or: How the Government Can Attract IT Pros During a Pay Freeze.

Letter sent to search giant asks about implications of new technology.

Global Strike Command will piggyback on a system already installed by Special Operations Command.

Agencies spend $2 billion a year on printing, only to throw away much of what they print the same day.

The Naval Post-Graduate School plans to buy tech that runs on open source infrastructure.

STEMM panelists say more mobility would help, too.

New research suggests that location plays a smaller role now in who we talk to and what we talk about.

Two of the wheels that control the direction in which the spacecraft points are broken.

International assistance agency seeks a platform to build and share new technology.

Agencies already hold critical tools to recruit and retain highly-skilled workers.

Safe Shepherd is a company that searches the web for all the public records available on its clients.

Agents scooped up medical records in a tax case, violating health privacy laws, California suit alleges.

The promise of delinking research and development from the actual manufacture of drugs, and why the pharmaceutical industry rejects an idea that could turn neglected diseases into profit.